Myopia

Kubota Vision Announces Publication in Scientific Reports; Effects of Using Projected Peripheral Myopic Defocus

Retrieved on: 
Thursday, July 14, 2022

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.
  • This was a 4-month prospective clinical study conducted at MVA to investigate the effects of using projected peripheral myopic defocus in a benchtop optical system.
  • The primary objective of the study was to assess the central axial length and cycloplegic refractive changes using a novel optical system and myopic defocus stimulus design.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

TQSKY launches T1 Smart Glasses for a Portable Entertainment Experience Like Never Before

Retrieved on: 
Thursday, July 7, 2022

NEW YORK, July 7, 2022 /PRNewswire/ -- TQSKY, a newcomer in the consumer technology offering world class experiences, is releasing the world's first audio-visual glasses, TQSKY T1, on Kickstarter today. Slim, light, and fashionable, these AR/XR glasses seek to change how consumers view entertainment options on the go or in the comfort of their own homes.

Key Points: 
  • NEW YORK, July 7, 2022 /PRNewswire/ -- TQSKY, a newcomer in the consumer technology offering world class experiences, is releasing the world's first audio-visual glasses, TQSKY T1, on Kickstarter today.
  • Slim, light, and fashionable, these AR/XR glasses seek to change how consumers view entertainment options on the go or in the comfort of their own homes.
  • The TQSKY T1 is also adjustable for 0-600 myopia.
  • Immersive and CD-grade audio quality: The only audiovisual glasses with Hi-Res sound quality certification that does not require headphones to enjoy high-quality audio.

Worldwide Lens Industry to 2027 - Featuring Hoya, Eastman Kodak, Carl Zeiss and Fielmann Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022

They also offer protection to the eyes from environmental pollutants such as debris, wind and UV rays.

Key Points: 
  • They also offer protection to the eyes from environmental pollutants such as debris, wind and UV rays.
  • What are the various stages in the value chain of the global glass lens industry?
  • What is the structure of the global glass lens industry and who are the key players?
  • What is the degree of competition in the global glass lens industry?

Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China

Retrieved on: 
Wednesday, July 6, 2022

This marks the first time that a clinical trial has been approved in China to evaluate a pharmacologic treatment for presbyopia.

Key Points: 
  • This marks the first time that a clinical trial has been approved in China to evaluate a pharmacologic treatment for presbyopia.
  • In August 2020, Arctic Vision obtained from Eyenovia an exclusive license for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea.
  • Subsequent to this original agreement, Arctic Vision also licensed Eyenovias development-stage candidate for pharmacological mydriasis, MydCombi.
  • In parallel, Arctic Vision continues work on its other two Eyenovia licensed programs - pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi).

Outlook on the Therapeutics Contact Lens Global Market to 2027 - Featuring Alcon, Bausch Health Companies and Carl Zeiss Meditec Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022

Also, the increased prevalence of myopia and other eye disorders and the growing use of advanced technologies for eye treatment are other prominent factors driving the Global Therapeutics Contact Lens Market.

Key Points: 
  • Also, the increased prevalence of myopia and other eye disorders and the growing use of advanced technologies for eye treatment are other prominent factors driving the Global Therapeutics Contact Lens Market.
  • The government of several countries is investing heavily to develop the healthcare sector and emphasize the importance of vision care.
  • Also, an increase in the number of myopia and other eye disorders is expected to create significant opportunities for the Global Therapeutics Contact Lens Market in the forecast period.
  • The Global Therapeutics Contact Lens Market is segmented into material type, application, distribution channel, regional distribution, and competitive landscape.

OcuDoc Announces Appointment of Dr. Richard Lindstrom as Chief Medical Advisor, Ophthalmology

Retrieved on: 
Tuesday, June 21, 2022

COLUMBUS, Ohio, June 21, 2022 /PRNewswire/ -- Columbus-based ophthalmic MedTech startup, OcuDoc, announced the appointment of Dr. Richard Lindstrom as its new Chief Medical Advisor, Ophthalmology. The firm brings on Dr. Lindstrom to provide his extensive experience in cornea, cataract, glaucoma, laser surgery, refractive surgery, innovation and the business of ophthalmology. 

Key Points: 
  • Richard Lindstromas its new Chief Medical Advisor, Ophthalmology.
  • The firm brings on Dr. Lindstrom to provide his extensive experience in cornea, cataract, glaucoma, laser surgery, refractive surgery, innovation and the business of ophthalmology.
  • OcuDoc has announced the appointment of Dr. Richard Lindstrom to serve as its Chief Medical Advisor, Ophthalmology.
  • "We are thrilled to have Dr. Lindstrom, a 50-year industry veteran, join our organization as a Medical Advisor.

New Study Finds Children with Vision Impairment More Likely to Suffer from Depression and Anxiety

Retrieved on: 
Monday, June 20, 2022

In addition, findings indicated that surgery to correct strabismus (misalignment of the eyes) significantly improved symptoms of depression and anxiety in children.

Key Points: 
  • In addition, findings indicated that surgery to correct strabismus (misalignment of the eyes) significantly improved symptoms of depression and anxiety in children.
  • The study, which was published in the peer-reviewed journal Ophthalmology, builds our understanding of the link between vision impairment, strabismus and children's mental health.
  • The new study builds our understanding of the link between vision impairment, strabismus, and children's mental health.
  • Globally, an estimated 19 million children below the age of 14 years have vision impairment or are blind.

Seoul Semiconductor: The #1 in Patent Power Pre-empting the Future with 2nd Generation LED Technologies

Retrieved on: 
Friday, June 17, 2022

In addition, Seoul is 100% vertically integrated with production capacity for all of these technologies: from wafers and chips to packages and modules.

Key Points: 
  • In addition, Seoul is 100% vertically integrated with production capacity for all of these technologies: from wafers and chips to packages and modules.
  • Seoul is investing nearly $100 million in R&D every year and pouring out innovative LED technologies at a staggering rate.
  • Almost none of the LED products in the world today can be produced unless Seoul approves the use of its patents.
  • Seoul Semiconductor is the worlds second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents.

ALL ABOUT VISION RELEASES COMPREHENSIVE INFORMATION HUB IN RESPONSE TO THE GROWING MYOPIA CRISIS

Retrieved on: 
Thursday, June 16, 2022

DALLAS, June 16, 2022 /PRNewswire/ -- All About Vision (AAV), the world's leading online portal for vision and eye care information, has launched a myopia information hub. Myopia has rapidly increased in prevalence worldwide, with an estimated 50% of the global population diagnosed by 2050. The hub contains the most updated information on myopia with more than 100 pieces of content.

Key Points: 
  • DALLAS, June 16, 2022 /PRNewswire/ -- All About Vision (AAV), the world's leading online portal for vision and eye care information, has launched a myopia information hub .
  • The hub contains the most updated information on myopia with more than 100 pieces of content.
  • All About Vision worked with researchers from the International Myopia Institute , the WHO , the Brien Holden Vision Institute and others to incorporate the latest data to create accessible content for the myopia hub.
  • "With the growing prevalence of myopia, we are prepared to remain ahead of the curve to meet readers where they are in their search for information."

Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries

Retrieved on: 
Tuesday, June 14, 2022

This agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 in Europe and other select countries.

Key Points: 
  • This agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 in Europe and other select countries.
  • NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17.
  • In addition, Vyluma will be entitled to tiered royalty payments, ranging from the mid to upper teens, on net sales of NVK002 under the expanded agreement.
  • To learn more about Tha, visit https://www.laboratoires-thea.com/en
    Investor Contact for Nevakar and Vyluma: